The oropharyngeal delivery of interferons: Where are we and where do we need to go?

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 859-861

  Bocci, V ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

DRUG ABSORPTION; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; OROPHARYNX; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; HUMANS; INTERFERONS; INTESTINAL ABSORPTION; LYMPHOID TISSUE; OROPHARYNX;

EID: 0032839270     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313361     Document Type: Review

References (28)

1. CUMMINS, J.M., and GEORGIADES, J.A. (1993). How it began. Arch. Immunol. Ther. Exp. 41, 169-172.
2. HULTON, M.R., LEVIN, D.L., and FREEDMAN, L.S. (1992). Randomized, placebo-controlled, double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J. Acq. Immun. Defic. Syndrome 5, 1084-1090.
3. ser. J. Interferon Res. 12, 411-413.
4. DHINGRA, K., DUVIC, M., HYMES, S., MCLAUGHLIN, P., ROTHBERG, J., and GUTTERMAN, J.U. (1993). A phase-I clinical study of low-dose oral interferon-α. J. Immunother. 14, 51-55.
5. ZIELINSKA, W., PASZKIEWICZ, J., KORCZAK, A., WLASIUK, M., ZÓLTOWSKA, A., SZUTOWICZ, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch. Immunol. Ther. Exp. 41, 253-257.
6. BOCCI, V. (1981). Production and role of interferon in physiological conditions. Biol. Rev. 56, 49-85.
7. BOCCI, V. (1988). Roles of interferon produced in physiological conditions. A speculative review. Immunology 64, 1-9.
8. BOCCI, V. (1985). Immunomodulators as local hormones: new insights regarding their clinical utilization. J. Biol. Resp. Modif. 4, 340-352.
9. BOCCI, V. (1987). Metabolism of protein anticancer agents. Pharmacol. Ther. 34, 1-49.
10. BOCCI, V. (1992). Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. Crit. Rev. Ther. Drug Carr. Syst. 9, 91-133.
11. BOCCI, V., VON BREMEN, K., CORRADESCHI, F., FRANCHI, F., LUZZI, E., and PAULESU, L. (1993). Presence of interferon-gamma and interleukin-6 in colostrum of normal women. Lymphokine Cytokine Res. 12, 21-24.
12. BRYAN, D.L., HAWKES, J.S., and GIBSON, R.A. (1999). Interleukin-12 in human milk. Pediat. Res. 45, 858-859.
13. BOCCI, V., VON BREMEN, K., CORRADESCHI, F., LUZZI, E., and PAULESU, L. (1991). What is the role of cytokines in human colostrum? J. Biol. Regulat. Homeost. Agent. 5, 121-124.
14. BOCCI, V. (1991). Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Does an unorthodox route improve the therapeutic index of interferon? Clin. Pharmacokinet. 21, 411-417.
15. FLEISCHMANN, W.R., JR., FIELDS, E.E., WANG, J.L., HUGHES, T.K. and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc. Soc. Exp. Biol. Med. 197, 424-430.
16. FLEISCHMANN, W.R., JR., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
17. FLEISCHMANN, W.R., JR., MASOOR, J., WU, T.Y., and FLEISCHMANN, C.M. (1998). Orally administered IFN-α acts alone and in synergistic combination with intraperitoneally administered IFN-γ to exert an antitumor effect against B16 melanoma in mice. J. Interferon Cytokine Res. 18, 17-20.
18. 2 in rats. Int. J. Pharm. 46, 199-202.
19. BROD, S.A., KHAN, M., KERMAN, R.H., and PAPPOLLA, M. (1995). Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58, 61-69.
20. BROD, S.A., SCOTT, M., BURNS, D.K., and PHILLIPS, J.T. (1995). Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J. Interferon Cytokine Res. 15, 115-122.
21. BROD, S.A., KERMAN, R.H., NELSON, L.D., MARSHALL, G.D., JR., HENNINGER, E.M., KHAN, M., JIN, R., and WOLINSKY, J.S. (1997). Ingested IFN-α has biological effects in humans with relapsing -remitting multiple sclerosis. Multiple Sclerosis 3, 1-7.
22. BROD, S.A., MALONE, M., DARCAN, S., PAPOLLA, M., and NELSON, L. (1998). Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice. Diabetologia 41, 1227-1232.
23. KOECH, D.K., OBEL, A.O., MINOWADA, J., HUTCHINSON, V.A., and CUMMINS, J.M. (1990). Low dose oral alpha Interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol. Biother. 2, 91-95.
24. LECCIONES, J.A., ABEJAR, N.H., DLMAANO, E.E., BARTOLOME, R., CINCO, S., MARIANO, N., YERRO, M.E., COBAR, S., and FUGGAN, B. (1998). A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J. Interferon Cytokine Res. 18, 647-652.
25. NAGAO, Y., YAMASHIRO, K., HARA, N., HORISAWA, Y., KATO, K., and UEMURA, A. (1998). Oral-mucosal administration of IFN-α potentiates immune response in mice. J. Interferon Cytokine Res. 18, 661-666.
26. BOCCI, V., CORRADESCHI, F., NALDINI, A., and LENCIONI, E. (1986). Enteric absorption of human interferons α and β in the rat. Int. J. Pharm. 34, 111-114.
27. KIMURA, K., and BEIDLER, L.M. (1961). Microelectrode study of taste receptors of rat and hamster. J. Cell. Comp. Physiol. 58, 131-139.
28. TATEDA, H., and BEIDLER, L.M. (1964). The receptors potential of the taste cell of the rat. J. Gen. Physiol. 47, 479-487.